Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.13−0.39 (-0.32%)
Close on Nov 18, 2026Market cap $10.34BP/E –Yield –
Kymera Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Kymera Therapeutics's price to sales ratio was 106.3× on Nov 11, 2026, against 111.3× a year earlier. Over the last 5 years it ranged from 11.6× to 189.5×, with a median of 34.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 106.3× | −21.3 |
| 2025 | Dec 31, 2025 | 127.6× | +97.9 |
| 2024 | Dec 31, 2024 | 29.7× | −0.4 |
| 2023 | Dec 29, 2023 | 30.1× | +0.4 |
| 2022 | Dec 30, 2022 | 29.7× | −16.5 |
| 2021 | Dec 31, 2021 | 46.3× | −73.1 |
| 2020 | Dec 31, 2020 | 119.4× | – |
See a number that looks wrong?